Moffitt Cancer Center and AstraZeneca have forged a strategic partnership to advance the development of cell therapies, particularly CAR-T and TCR-T treatments.
This collaboration leverages Moffitt’s clinical expertise and extensive network of cancer centers to accelerate AstraZeneca’s pipeline of cell therapies. AstraZeneca accesses Moffitt’s leading clinical environment and physician-scientist connections, facilitating the swift investigation of novel cell therapies.
Cell therapies have revolutionized cancer care, offering new treatment options for cancers with limited alternatives. Moffitt’s pivotal role in the clinical trials leading to FDA approvals for cell therapies demonstrates its capabilities in this field.
The partnership aims to overcome challenges in cell therapy development and expand access to these treatments. The focus is on conducting clinical studies for solid tumors and optimizing clinical operations to enhance the delivery of autologous cell therapies.
Patrick Hwu, Moffitt’s president and CEO, indicated that the collaboration with AstraZeneca will accelerate the development and delivery of cell therapies, enabling them to bring innovative treatments to patients faster and more efficiently.
Carsten Linnemann, AstraZeneca’s Head of Oncology Cell Therapy Clinical Development, suggested that the collaboration strengthens their connections with Moffitt, allowing them to accelerate the development of our autologous cell therapy pipeline and redefine cancer treatment for patients facing hematological and solid cancers.
Moffitt’s dedication to cancer prevention and cure as a National Cancer Institute-designated Comprehensive Cancer Center aligns with AstraZeneca’s global leadership in oncology. This partnership harnesses their combined expertise to advance cell therapy research and improve cancer treatment outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.